Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
1
13%
Ph phase_3
5
63%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(6)

Detailed Status

Completed6
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 21 (12.5%)
Phase 35 (62.5%)

Trials by Status

completed675%
not_yet_recruiting225%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema

NCT05355818
not_yet_recruitingphase_2

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

NCT07487948
not_yet_recruitingphase_3

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

NCT07335588
completedphase_3

A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema

NCT06004050
completedphase_3

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

NCT05259722
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05355818Phase 3

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema

Completed
NCT07487948Phase 2

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Not Yet Recruiting
NCT07335588Phase 3

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

Not Yet Recruiting
NCT06004050Phase 3

A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema

Completed
NCT05259722Phase 3

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

Completed
NCT04949841Phase 3

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials

Completed
NCT05486117Phase 1

Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema

Completed
NCT03826901Phase 1

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8